[Human stool vimentin, oncostatin M receptor and tissue factor pathway inhibitor 2 gene methylation analysis for the detection of colorectal neoplasms].
OBJECTIVE
To explore the feasibility of detecting vimentin, oncostatin M receptor (OMSR) and tissue factor pathway inhibitor 2 (TFPI2) gene methylation status in stool samples as a noninvasive screening tool for colorectal cancer and precancerous lesions.


METHODS
Stool samples were collected from 60 patients with colorectal cancer, 17 patients with adenoma and 30 normal volunteers. And fecal DNA was extracted and vimentin, OMSR and TFPI2 gene methylation status was analyzed by methylation-specific polymerase chain reaction (MSP).


RESULTS
The methylated vimentin, OMSR and TFPI2 was detected in 53.3% (32/60), 68.3% (41/60) and 75.0% (45/60) of colorectal cancer, and 5, 7 and 11 cases of colorectal adenoma respectively. The sensitivities of combined study, using three markers for the detection of colorectal cancer and colorectal adenomas, were 86.7% (26/30) and 76.5% (13/17) respectively. And the specificity was 86.7% (52/60).


CONCLUSIONS
As a feasible epigenetic marker, promoter hypermethylation for vimentin, OMSR and TFPI2 in stool samples is a sensitive, specific and noninvasive alternative for colorectal cancer screening.
Department of Gastroenterology, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Jin-Ping
JP
Zhang
Jing
J
Wang
Yin-Li
YL
Gui
Qiong-Qiong
QQ
Zhu
Zhi-Wei
ZW
Xu
Jian-Sheng
JS
Li
D014408:Biomarkers, Tumor / Q000378:metabolism; D015179:Colorectal Neoplasms; D019175:DNA Methylation; D005243:Feces; D006801:Humans; D053677:Receptors, Oncostatin M; D014746:Vimentin / Q000378:metabolism
D014408:Biomarkers, Tumor; D053677:Receptors, Oncostatin M; D014746:Vimentin